Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 112022

Result Summary for 112022

Result Summary

Protocol ID:	112022
Clinical Study ID:	112022
Official Title:	Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects
Phase:	phase 3
Study Indications or Diseases:	Infections, Papillomavirus
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Zhu F-C et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls aged 9–17 years. Abstract presented at the Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN), Hong Kong, 13-15 July 2012.